{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:11:02Z","timestamp":1794003062318,"version":"4.8.0"},"reference-count":75,"publisher":"European Respiratory Society (ERS)","issue":"167","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,9,27]]},"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:p>This meta-analysis explored the safety and effectiveness of mucolytics as an add-on treatment for chronic obstructive pulmonary disease (COPD) exacerbations. Based on a pre-registered protocol and following Cochrane methods, we systematically searched for relevant randomised or quasi-randomised controlled trials (RCTs). We used the Risk of Bias v2 tool for appraising the studies and performed random-effect meta-analyses when appropriate. We assessed certainty of evidence using GRADE. This meta-analysis included 24 RCTs involving 2192 patients with COPD exacerbations, entailing at least some concerns of methodological bias. We demonstrated with moderate certainty that mucolytics increase the rate of treatment success (relative risk 1.37, 95% CI 1.08\u20131.73, n=383), while they also exert benefits on overall symptom scores (standardised mean difference 0.86, 95% CI 0.63\u20131.09, n=316), presence of cough at follow-up (relative risk 1.93, 95% CI 1.15\u20133.23) and ease of expectoration (relative risk 2.94, 95% CI 1.68\u20135.12). Furthermore, low or very low certainty evidence suggests mucolytics may also reduce future risk of exacerbations and improve health-related quality of life, but do not impact on breathlessness, length of hospital stay, indication for higher level of care or serious adverse events. Overall, mucolytics could be considered for COPD exacerbation management. These findings should be validated in further, rigorous RCTs.<\/jats:p>","DOI":"10.1183\/16000617.0141-2022","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T12:35:27Z","timestamp":1674650127000},"page":"220141","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis"],"prefix":"10.1183","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-0842","authenticated-orcid":false,"given":"Efthymia","family":"Papadopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-9040","authenticated-orcid":false,"given":"Zsofia","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3942","authenticated-orcid":false,"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5102-0480","authenticated-orcid":false,"given":"Stavros","family":"Tryfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-6362","authenticated-orcid":false,"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-9616","authenticated-orcid":false,"given":"Alexander G.","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2024102404092259000_32.167.220141.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"2024102404092259000_32.167.220141.2","unstructured":"World Health Organization . Chronic obstructive pulmonary disease (COPD). www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd) Date last accessed: 27 May 2022. Date last updated: 20 May 2022."},{"key":"2024102404092259000_32.167.220141.3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/COPD.S3385","article-title":"Exacerbation rate, health status and mortality in COPD--a review of potential interventions","volume":"4","author":"Seemungal","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102404092259000_32.167.220141.4","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.041806"},{"key":"2024102404092259000_32.167.220141.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201412-2269OC"},{"key":"2024102404092259000_32.167.220141.6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0289-2020"},{"key":"2024102404092259000_32.167.220141.7","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . 2022 GOLD Reports. https:\/\/goldcopd.org\/2022-gold-reports-2\/ Date last accessed: 10 May 2022."},{"key":"2024102404092259000_32.167.220141.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01655-2017"},{"key":"2024102404092259000_32.167.220141.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2024102404092259000_32.167.220141.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02058-2018"},{"key":"2024102404092259000_32.167.220141.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02426-2016"},{"key":"2024102404092259000_32.167.220141.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214484"},{"key":"2024102404092259000_32.167.220141.13","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0073-2016"},{"key":"2024102404092259000_32.167.220141.14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","article-title":"Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial","volume":"7","author":"Sivapalan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102404092259000_32.167.220141.15","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0151TR"},{"key":"2024102404092259000_32.167.220141.16","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0436SF"},{"key":"2024102404092259000_32.167.220141.17","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003510"},{"key":"2024102404092259000_32.167.220141.18","doi-asserted-by":"publisher","DOI":"10.1080\/15412550500218098"},{"key":"2024102404092259000_32.167.220141.19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287.pub6"},{"key":"2024102404092259000_32.167.220141.20","unstructured":"Papadopoulou E , Tryfon S , Kostikas K , et al. Mucolytics as add-on treatment for acute exacerbations of chronic obstructive pulmonary disease. PROSPERO 2022: CRD42022314958. www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022314958"},{"key":"2024102404092259000_32.167.220141.21","unstructured":"Higgins JPT , Thomas J , Chandler J , et al. eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org\/handbook"},{"key":"2024102404092259000_32.167.220141.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2024102404092259000_32.167.220141.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2024102404092259000_32.167.220141.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02006-2021"},{"key":"2024102404092259000_32.167.220141.25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/biomedicines9121837","article-title":"Assessing treatment success or failure as an outcome in randomised clinical trials of COPD exacerbations. A Meta-Epidemiological Study","volume":"9","author":"Mathioudakis","year":"2021","journal-title":"Biomedicines"},{"key":"2024102404092259000_32.167.220141.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2024102404092259000_32.167.220141.27","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"2024102404092259000_32.167.220141.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2024102404092259000_32.167.220141.29","first-page":"65","article-title":"Multicenter, doubleblind study of oral acetylcysteine vs. placebo","volume":"111","author":"Brocard","year":"1980","journal-title":"Eur J Respir Dis Suppl"},{"key":"2024102404092259000_32.167.220141.30","first-page":"325","article-title":"Erythromycin and bromhexine in acute exacerbations of chronic bronchitis. A study on sputum penetration and clinical effectiveness","volume":"63","author":"Maesen","year":"1982","journal-title":"Eur J Respir Dis"},{"key":"2024102404092259000_32.167.220141.31","first-page":"612","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study)","volume":"33","author":"Marchioni","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2024102404092259000_32.167.220141.32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bdd.2510160504","article-title":"Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation","volume":"16","author":"Paganin","year":"1995","journal-title":"Biopharm Drug Dispos"},{"key":"2024102404092259000_32.167.220141.33","first-page":"969","article-title":"Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis","volume":"37","author":"Peralta","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"2024102404092259000_32.167.220141.34","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-36122"},{"key":"2024102404092259000_32.167.220141.35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000238595","article-title":"Serum, sputum and bronchial concentrations of erythromycin in chronic bronchitis after single and multiple treatments with either propionate-N-acetylcysteinate or stearate erythromycin","volume":"34","author":"Ricevuti","year":"1988","journal-title":"Chemotherapy"},{"key":"2024102404092259000_32.167.220141.36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12931-020-01610-x","article-title":"Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study","volume":"22","author":"Galdi","year":"2021","journal-title":"Respir Res"},{"key":"2024102404092259000_32.167.220141.37","first-page":"239","article-title":"Wp\u0142yw leczenia wziewna postacia ambroksolu na objawy kliniczne i wybrane parametry wentylacji u chorych hospitalizowanych z powodu zaostrzenia przewlek\u0142ej obturacyjnej choroby p\u0142uc [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients]","volume":"11","author":"Jahnz-R\u00f3zyk","year":"2001","journal-title":"Pol Merkur Lekarski"},{"key":"2024102404092259000_32.167.220141.38","doi-asserted-by":"crossref","first-page":"A786","DOI":"10.1016\/j.chest.2017.08.817","article-title":"Nebulized hypertonic saline for inpatient use in COPD","volume":"152","author":"Patel","year":"2017","journal-title":"Chest"},{"key":"2024102404092259000_32.167.220141.39","first-page":"1141","article-title":"Application of N-acetylcysteine inhalation in treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"45","author":"Ren","year":"2019","journal-title":"J Jilin Univ Med Ed"},{"key":"2024102404092259000_32.167.220141.40","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-010-0131-y"},{"key":"2024102404092259000_32.167.220141.41","first-page":"337","article-title":"Efficacy of ambroxol hydrochloride intravenous injection adjunctive treatment for acute exacerbation of chronic obstructive pulmonary disease","volume":"16","author":"Zhang","year":"2013","journal-title":"Pract Pharm Clin Remedies"},{"key":"2024102404092259000_32.167.220141.42","first-page":"e6073","article-title":"N-acetylcysteine in the management of acute exacerbation of chronic obstructive pulmonary disease","volume":"11","author":"Ansari","year":"2019","journal-title":"Cureus"},{"key":"2024102404092259000_32.167.220141.43","unstructured":"ClinicalTrials.gov . Nebulized hypertonic saline for inpatient use in COPD. ClinicalTrials.gov identifier: NCT02266875 . https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02266875 Date last updated: 22 November 2017. Date last accessed: 4 July 2022."},{"key":"2024102404092259000_32.167.220141.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)90835-4"},{"key":"2024102404092259000_32.167.220141.45","unstructured":"Clinical Trial Report Synopsis Study 7171L01. A randomized, double-blind, placebo controlled, parallel groups study on efficacy and safety of NAC 600 mg daily and NAC 1200 mg daily as mucolytic agent in the treatment of chronic obstructive pulmonary disease (COPD) exacerbation. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004048-21\/results Date last updated: 23 April 2016."},{"key":"2024102404092259000_32.167.220141.46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2147\/COPD.S87091","article-title":"Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD","volume":"10","author":"Moretti","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102404092259000_32.167.220141.47","first-page":"378","article-title":"Effects of erdosteine on serum biomarker concentrations at COPD exacerbation","volume":"36","author":"Bianchi","year":"2010","journal-title":"Eur Respir J"},{"key":"2024102404092259000_32.167.220141.48","first-page":"536","article-title":"Effect of erdosteine on airflow obstruction and symptom recovery in severe COPD exacerbations","volume":"38","author":"Moretti","year":"2011","journal-title":"Eur Respir J"},{"key":"2024102404092259000_32.167.220141.49","first-page":"2881","article-title":"Acute effect of erdosteine on preventing recurrence of exacerbation in COPD patients after hospital discharge","volume":"40","author":"Moretti","year":"2012","journal-title":"Eur Respir J"},{"key":"2024102404092259000_32.167.220141.50","first-page":"35","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment","volume":"4","author":"Mohanty","year":"2001","journal-title":"J Clin Res"},{"key":"2024102404092259000_32.167.220141.51","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525060-00005"},{"key":"2024102404092259000_32.167.220141.52","first-page":"89","article-title":"Mucolytic activity of erdosteine: Double blind clinical trial vs. placebo","volume":"47","author":"Bisetti","year":"1995","journal-title":"Arch Medicina Interna"},{"key":"2024102404092259000_32.167.220141.53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00508-014-0692-4","article-title":"N-acetylcysteine in patients with COPD exacerbations associated with increased sputum","volume":"127","author":"Aytemur","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"2024102404092259000_32.167.220141.54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-4-13"},{"key":"2024102404092259000_32.167.220141.55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejcdt.2013.02.012","article-title":"High dose N-acetyl cysteine improves inflammatory response and outcome in patients with COPD exacerbations","volume":"62","author":"El Hafiz","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"Suppl. 60","key":"2024102404092259000_32.167.220141.56","first-page":"A4077","article-title":"Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)","volume":"48","author":"Moretti","year":"2016","journal-title":"Eur Respir J"},{"key":"2024102404092259000_32.167.220141.57","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.5.8630597"},{"key":"2024102404092259000_32.167.220141.58","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S38938"},{"key":"2024102404092259000_32.167.220141.59","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09071523"},{"key":"2024102404092259000_32.167.220141.60","doi-asserted-by":"crossref","first-page":"e120901","DOI":"10.1172\/JCI120901","article-title":"Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease","volume":"132","author":"Singanayagam","year":"2022","journal-title":"J Clin Invest"},{"key":"2024102404092259000_32.167.220141.61","first-page":"1956","article-title":"Effect of eucalyptus on pulmonary function and oxidative stress in patients with acute exacerbation of pulmonary chronic obstructive pulmonary disease","volume":"18","author":"Chen","year":"2018","journal-title":"Prog Mod Biomed"},{"key":"2024102404092259000_32.167.220141.62","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0011-393X(01)80090-4","article-title":"Neltenexine versus carbocysteine in the treatment of exacerbations of mild chronic obstructive pulmonary disease: a randomized, controlled, open-label study","volume":"62","author":"D'Elia","year":"2001","journal-title":"Curr Ther Res Clin Exp"},{"key":"2024102404092259000_32.167.220141.63","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1378\/chest.132.4_MeetingAbstracts.529","article-title":"Comparative evaluation of the efficacy, safety and tolerability of the fixed dose combinations of cefixime plus erdosteine and amoxicillin plus bromhexine in patients with acute exacerbations of chronic bronchitis","volume":"132","author":"Sharma","year":"2007","journal-title":"Chest"},{"key":"2024102404092259000_32.167.220141.64","first-page":"1353","article-title":"Clinical and functional effects of domiodol and sobrerol in hypersecretory bronchopneumonias","volume":"72","author":"Finiguerra","year":"1981","journal-title":"Minerva Med"},{"key":"2024102404092259000_32.167.220141.65","first-page":"313","article-title":"Efficacy, safety and tolerability of salbutamol+guaiphenesin+bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study","volume":"108","author":"Prabhu Shankar","year":"2010","journal-title":"J Indian Med Assoc"},{"key":"2024102404092259000_32.167.220141.66","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00016"},{"key":"2024102404092259000_32.167.220141.67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/M19-3007","article-title":"Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis","volume":"172","author":"Dobler","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024102404092259000_32.167.220141.68","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.21037\/apm-21-1138","article-title":"Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease","volume":"10","author":"Jiang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2024102404092259000_32.167.220141.69","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2022 report. https:\/\/goldcopd.org\/2022-gold-reports-2\/ Date last accessed: 4 July 2022."},{"key":"2024102404092259000_32.167.220141.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00791-2016"},{"key":"2024102404092259000_32.167.220141.71","unstructured":"Yang I , Dabscheck E , George J , et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2021. https:\/\/copdx.org.au\/wp-content\/uploads\/2021\/04\/COPDX-V2-63-Feb-2021_FINAL-PUBLISHED.pdf Date last accessed: 4 July 2022."},{"key":"2024102404092259000_32.167.220141.72","unstructured":"National Institute for Health and Care Excellence . Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk\/guidance\/ng115\/chapter\/Recommendations. Date last accessed: 4 July 2022. Date last updated: 26 July 2019."},{"key":"2024102404092259000_32.167.220141.73","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00006"},{"key":"2024102404092259000_32.167.220141.74","doi-asserted-by":"publisher","DOI":"10.1177\/1753465810374611"},{"key":"2024102404092259000_32.167.220141.75","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00627-2020"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0141-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:39Z","timestamp":1740355539000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0141-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":75,"journal-issue":{"issue":"167","published-online":{"date-parts":[[2023,1,25]]},"published-print":{"date-parts":[[2023,3,31]]}},"alternative-id":["10.1183\/16000617.0141-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0141-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}